# A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma

> **NCT06471257** · PHASE3 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 790 (estimated)

## Conditions studied

- Asthma

## Interventions

- **COMBINATION_PRODUCT:** Budesonide/Albuterol metered dose inhaler, MDI
- **COMBINATION_PRODUCT:** Albuterol sulfate metered dose inhaler, MDI

## Key facts

- **NCT ID:** NCT06471257
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-17
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 790 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06471257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06471257, "A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06471257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*